

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role	Buňky	Zdroj
miR-133a-3p	Rakovina močového měchýře	PNP	Tumor supresor		(Yamasaki et al., 2012)
	Rakovina prostaty	PNP	Tumor supresor	PC3, DU145	(Kojima et al., 2012)
	Rakovina močového měchýře	TAGLN2	Tumor supresor	BOY, T24	(Yoshino et al., 2011)
	Karcinom plic	TGFBR1, EGFR, IGF-1R	Tumor supresor	CL-1-5, A549	(Wang et al., 2014a)
	Rakovina vaječníků	IGFR1R	Tumor supresor	SW626, SKOV-3, OVCAR-3	(Guo et al., 2014)
	Hepatocelulární karcinom	IGRF1R	Tumor supresor	Hep3B, HepG2, Huh-7	(Zhang et al., 2015)
	Rakovina prsu	EGFR	Tumor supresor	MCF-7, MDA-MB-231	(Cui et al., 2013)
	Děložního čípku	EGFR	Tumor supresor	HeLa	(Liu et al., 2008)
miR-143-3p	Orální spinocelulární karcinom	HK2	Tumor supresor	OECM-1, Tca8113	(Sun and Zhang, 2017)
	Orální spinocelulární karcinom	c-MET	Tumor supresor	Tca-8113, CAL-27	(Xu et al., 2015a)
	Spinocelulární karcinom hlavy a krku	MDM2	Tumor supresor	TE-12, NH30, SCC-25, NCI-H226	(Zhang et al., 2013)
	Spinocelulární karcinom hlavy a krku	HK2	Tumor supresor	JHU-012, JHU-022	(Peschiaroli et al., 2013)
	Rakovina děložního hrdla	BCL-2	Tumor supresor	Saos2	(Gómez-Gómez et al., 2016)
	Kolorektální karcinom	DNMT3A	Tumor supresor	228, SW480	(Ng et al., 2009)
	Rakovina vaječníků	TAK1	Tumor supresor	SKOV-3, ES2, OVCAR-3	(Shi et al., 2018)
	Karcinom dlaždicových buněk jícnu	QKI-5	Tumor supresor	Kyse30, Kyse70, Eca109	(He et al., 2016)
miR-145-5p	Kolorektální karcinom	E2F5, BAG4, FMNL2	Tumor supresor	SW480, SW620	(Xie et al., 2016)
	Rakovina děložního čípku	c-Myc	Tumor supresor	C33A	(Shi et al., 2012)
	Kolorektální karcinom	PAK4	Tumor supresor	SW1116, HCT1116	(Sheng et al., 2017)
	Kolorektální karcinom	TUSC3	Tumor supresor	LS174T, HCT116	(Tang et al., 2019)
	Kolorektální karcinom	P70S6K1	Tumor supresor	SW1116, SW480	(Xu et al., 2012)
	Kolorektální karcinom	SOX9	Tumor supresor	DLD-1, HT-29	(Xu et al., 2018)
	Kolorektální karcinom	MYO6	Tumor supresor	SW620, HCT116	(Wei and Li, 2017)

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role	Buňky	Zdroj
miR-145-5p	Kolorektální karcinom	MYO6	Tumor supresor	SW620, HCT116	(Wei and Li, 2017)
	Kolorektální karcinom	IRS-1	Tumor supresor		(Shi et al., 2007)
	Kolorektální karcinom	SIP1	Tumor supresor	SW480, SW620	(Sathyanarayanan et al., 2018)
	Kolorektální karcinom	FSCN1	Tumor supresor	SW620, LoVo	(Feng et al., 2014)
	Močového měchýře	UHRF1	Tumor supresor	BOY, T24	(Matsushita et al., 2016)
	Prsu	ARF6	Tumor supresor	MCF7	(Eades et al., 2015)
	Prsu	JAM-A, c-Myc, ROCK1, CCNE2, OCT4, MMP11, RTKN, MUC1, FSCN1	Tumor supresor		(Xu et al., 2019b)
	Nemalobuněčný karcinom plic	MUC1, NEDD9, FOXM1, MTDH, FSCN1	Tumor supresor		(Xu et al., 2019b)
	Glioblastom	ADAM17, EGFR, ROCK1, ABCG2, CTFG, SOX9, ADD3	Tumor supresor		(Xu et al., 2019b)
	Osteosarkom	MTDH, RASA1, DNMT3A, HK2, HMGA	Tumor supresor		(Xu et al., 2019b)
	Močového měchýře	PAK1, ZEB1/2, FSCN1, KLF4, CDK6, Sp1	Tumor supresor		(Xu et al., 2019b)
	Prostaty	FSCN1, SWAP70, HEF1	Tumor supresor		(Xu et al., 2019b)
	Žaludku	FSCN1, Ets1, SOX9, CTNND1, N-cadherin, ZEB2	Tumor supresor		(Xu et al., 2019b)
	Děložního čípku	SIP1, MYPT1	Tumor supresor		(Xu et al., 2019b)
	Další rakoviny				(Xu et al., 2019b)
	Laryngeální spinocelulární karcinom		Tumor supresor	AMC-HN-8	(Ye et al., 2019)
	Děložního čípku	WNT2B	Tumor supresor	HeLa, SiHa	(Li et al., 2019b)
Vaječníků	c-Myc	Tumor supresor	SKOV-3, 3AO	(Li et al., 2020a)	

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-133b	Cervikální karcinom	MST2, CDC42, RHOA	Tumor supresor	CaSki	(Qin et al., 2012)
	Kolorektální karcinom	MET	Tumor supresor	SW-620, HT-29	(Hu et al., 2010)
	Spinocelulární karcinom jazyka	PKM2	Tumor supresor	Cal27	(Wong et al., 2008)
	Karcinom dlaždicových buněk jícnu	FSCN1	Tumor supresor	TE2, TE3, TE12, TE13	(Kano et al., 2010)
	Spinocelulárním karcinomu jazyka	PKM2	Tumor supresor	Cal27, HN21B, HN96	(Wong et al., 2008)
	Rakovina plic	PKM2	Tumor supresor	A549	(Liu et al., 2016)
	Osteosarkom	BCL2L2, MCL-1, IGF1R, MET, FAK	Tumor supresor	U2-OS, MG-63	(Zhao et al., 2013)
	Rakovina plic	MCL-1, BCL2L2	Tumor supresor	H2009	(Crawford et al., 2009)
	Rakovina močového měchýře	Bcl-w, Akt1	Tumor supresor	T24	(Chen et al., 2014)
	Rakovina plic	SOX9	Tumor supresor	H1299	(Liu et al., 2020a)
	Rakovina vaječníků	PKM2	Tumor supresor	SKOV-3, 3AO	(Li et al., 2020a)
	Rakovina prostaty	FAIM	Tumor supresor	HeLa	(Farooqi et al., 2014)
miR-762	Spinocelulární karcinom hlavy a krku	PHLPP2, FOXO4	Onkogen	CAL27, SCC-9	(Chen et al., 2019b)
	Rakovina prsu	IRF7	Onkogen	MCF-7, MDA-MB-231	(Li et al., 2015a)
	Rakovina vaječníků	Menin	Onkogen	SKOV-3, CAO V	(Hou et al., 2017)
	Nemalobuněčný karcinom plic	ABR	Onkogen	PC-9, A549	(Ge et al., 2019)
	Rakovina močového měchýře	$\Delta$ NP63	Onkogen	T24, 5637	(Liu et al., 2020c)
	Rakovina žaludku	AKNA	Onkogen	AGS, BGC-823	(Wang et al., 2020)
miR-142-3p	Orální spinocelulární karcinom		Tumor supresor		(Gao et al., 2013)
	Spinocelulární rakovina kůže		Tumor supresor		(Xia et al., 2018)
	Rakovina tlustého střeva	CD133, ABCG2, Lgr5	Tumor supresor	HT-29	(Shen et al., 2013)
	Lymfatická leukemie	MLL-AF4	Tumor supresor	RS4;11	(Dou et al., 2013)

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-142-3p	Rakovina: plic, jater, děložního čípku, prsu	CDC25C	Tumor supresor	A549, H1299; HepG2, Hep3B; HeLa, Caski; MCF-7, MDA-MB-231	(Cao et al., 2016)
	Lymfatická leukemie	cAMP, PAK, GR $\alpha$	Onkogen	Jurkat, MOLT-3	(Lv et al., 2012)
	Nasofaryngeální karcinom	SOCS6	Onkogen	CNE-2, SUNE-1	(Qi et al., 2015)
	Hepatocelulární karcinom	LDHA	Tumor supresor	SK-Hep-1 a Huh7	(Hua et al., 2018)
	Duktální adenokarcinom pankreatu	HSP70	Tumor supresor	PaCa-2, Capan-1, S2-013	(MacKenzie et al., 2013)
	Hepatocelulární karcinom	RAC1	Tumor supresor	QGY-7703, SMMC-7721	(Wu et al., 2011)
	Rakovina prsu	$\beta$ -katenin	Tumor supresor	MDA-MB-468, HCC1806, MCF-7	(Troschel et al., 2018)
	Glioblastom	TGF-p	Tumor supresor	M1, M2 makrofágy	(Xu et al., 2014)
	Hepatocelulární karcinom	CD133	Tumor supresor	Huh7, PLC8024	(Chai et al., 2014)
	Rakovina děložního čípku	FZD7	Tumor supresor	HeLa, SIHa	(Deng et al., 2015)
miR-451a	Rakovina žaludku	TSC1	Tumor supresor	AGS, MKN28, MKN45	(Riquelme et al., 2016)
	Rakovina trávicího traktu	MIF	Tumor supresor	AGS, DLD1	(Bandres et al., 2009)
	Glioblastom		Tumor supresor	A172, LN229, U251	(Nan et al., 2010)
	Kolorektální karcinom	CAB39, EMSY	Tumor supresor	HCT116	(Ruhl et al., 2018)
	Nemalobuněčný karcinom plic	PTEN	Tumor supresor	A549	(Tian et al., 2016)
	Rakovina štítné žlázy	MIF, c-MYC a AKT1	Tumor supresor	NIM, TPC1	(Minna et al., 2016)
	Hepatocelulární karcinom	YWHAZ	Tumor supresor	HepG2, Huh-7	(Wei et al., 2019)
	Rakovina tlustého střeva	YWHAZ	Tumor supresor	HCT116, HT29	(Li et al., 2015b)
	Rakovina štítné žlázy	PSMB8	Tumor supresor	B-CPAP, KTC-1	(Uchida et al., 2019)
	Kolorektální karcinom	BAP31	Tumor supresor	HCT116, SW620	(Xu et al., 2019a)
	Hypofaryngeálního spinocelulární karcinom	ESDN	Tumor supresor	FaDu, SAS	(Fukumoto et al., 2014)

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-451a	Bazocelulární karcinom	TBX1	Tumor supresor	TE 354.T	(Sun and Jiang, 2018)
	Karcinom ledvinových buněk	PMM2	Tumor supresor	786-O, A498	(Yamada et al., 2018a)
miR147b	Rakovina prsu		Tumor supresor	MDA-MB-231	(Zhang et al., 2016a)
	Kolorektální rakovina	NDUFA4	Tumor supresor	HCT-116, HT29, SW480, LoVo	(Cui et al., 2018)
	Kolorektální karcinom	UBE2N	Onkogen	HepG2, Huh 7, 293T, L02	(Zhang et al., 2017)
	Rakovina vaječníků		Tumor supresor	SKOV4	(Kleemann et al., 2017)
	Rakovina tlustého střeva	EMP1	Tumor supresor	HCT116, SW480	(Lee et al., 2014)
miR-30a-3p	Lymfatická leukemie	SOCS3	Onkogen	MDSC	(Xu et al., 2017)
	Glioblastom	PRDM1	Onkogen	LN229, U251	(Wang et al., 2013)
	Mozková ischemie (není rakovina)	Beclin 1	Onkogen		(Guo et al., 2017a)
	Karcinom dlaždicovitých buněk jícnu	WNT2, FZD2	Onkogen	KYSE30, KYSE150	(Qi et al., 2017)
	Orální spinocelulární karcinom	DNMT3B	Tumor supresor	OEC-M1, SCC-15	(Shiah et al., 2020)
	Nemalobuněčný karcinom plic	EPAS1	Tumor supresor	A549, SPCA1	(Yuan et al., 2019)
	Rakovina ledvin	HIF2 $\alpha$	Tumor supresor	RCC4, UMRC2	(Mathew et al., 2014)
	Rakovina žaludku	COX-2, BCL9	Tumor supresor	MKN45, SGC-7901	(Liu et al., 2017a)
	Nasofaryngeální karcinom	Rap1A	Tumor supresor	C666-1, 5-8F	(Hu et al., 2019)
	Rakovina tlustého střeva	HP1 $\gamma$ , DLT, PIK3CD, BECN1, IRS2, ITGB3	Tumor supresor		(Yang et al., 2017)
	Rakovina žaludku	Vimentin	Tumor supresor		(Yang et al., 2017)
	Rakovina plic	BCL11A, IGFR1, Snai1, PI3K/AKT	Tumor supresor		(Yang et al., 2017)
	Glioblastom	SEPT7, SOCS3	Onkogen		(Yang et al., 2017)
	Hepatocelulární karcinom	Snai1, MTDH, Vimentin, MMP3	Tumor supresor		(Yang et al., 2017)
	Rakovina prsu	EYA2, MTDH, Vimentin, Slug	Tumor supresor		(Yang et al., 2017)
	Další rakoviny				(Yang et al., 2017)

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-10a-5p	Nemalobuněčný karcinom plic	PTEN	Onkogen	SPC-A-1	(Yu et al., 2015)
	Rakovina děložního čípku	CHL1	Onkogen	HeLa, C33A	(Long et al., 2012)
	Rakovina slinivky	HOXB1, HOXB3	Onkogen	PaTu8988T, PaTu8988S	(Weiss et al., 2009)
	Rakovina žaludku	HOXA1	Tumor supresor	HGC-27, MGC-803	(Jia et al., 2014)
	Akutní myeloidní leukemie	MDM4	Onkogen	K-562	(Ovcharenko et al., 2011)
	Chronická myeloidní leukemie	USF2	Tumor supresor	KU812	(Agirre et al., 2008)
	Duktuální adenokarcinom pankretu	TFAP2C	Onkogen	AsPC-1, T3M4	(Xiong et al., 2018)
	Hepatocelulární karcinom	NCOR2	Onkogen	HEK293T, Huh7, HepG2-C3A, SK-Hep-1, MHCCLM3	(Wu et al., 2019b)
	Kolorektální karcinom	MMP14, ACTG1	Tumor supresor	SW480, SW620	(Liu et al., 2017b)
	Glioblastom	PTEN	Onkogen	U251, SHG-44	(Liu et al., 2013b)
	Rakovina děložního čípku	PTEN	Onkogen	HeLa, SiHa	(Zeng and Li, 2014)
	Hepatocelulární karcinom	EphA4	Onkogen	HepG2, QGY-7703	(Yan et al., 2013)
miR-145-3p	Rakovina prostaty	MELK, NCAPG, BUB1 a CDK1	Tumor supresor	PC3, DU145	(Goto et al., 2017)
	Karcinom dlaždicových buněk jícnu	DHRS2, MYO1B	Tumor supresor	TE-8, TE-9	(Shimonosono et al., 2019)
	Rakovina plic	LMNB2	Tumor supresor	A549, H1299	(Misono et al., 2018)
	Spinocelulární karcinom hlavy a krku	MYO1B	Tumor supresor	SAS, HSC3	(Yamada et al., 2018b)
	Rakovina močového měchýře	UHRF1	Tumor supresor	T24, BOY	(Matsushita et al., 2016)
	Nemalobuněčný karcinom plic	PDK1	Tumor supresor	A549, H1299	(Chen et al., 2018)
	Rakovina prsu	MYBL2	Tumor supresor	MDA-MB-435	(Chen and Chen, 2018)
	Rakovina plic	MTDH	Tumor supresor	SK-MES-1, EBC-1	(Mataki et al., 2016)
miR-9-5p	Rakovina prostaty	StarD13	Tumor supresor	DU145, PC-3	(Chen et al., 2019a)
	Rakovina slinivky	GOT1	Tumor supresor	BxPC3	(Wang et al., 2019)
	Rakovina štítné žlázy	BRAF	Tumor supresor	BCPAP	(Guo et al., 2018)

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-9-5p	Rakovina žaludku	LMX1A	Onkogen	AGS	(Zhang et al., 2018c)
	Melanom	GOT1	Onkogen	A375, G-361	(Zhang et al., 2018b)
	Rakovina plic	NFκB1	Tumor supresor	H1299	(Arora et al., 2011)
	Rakovina vaječníků	TLN1	Tumor supresor	SKOV-3, CAOV3, OVCAR3	(Tang et al., 2013)
	Glioblastom	FOXP2	Tumor supresor	U251, A118MG, U87MG	(Zhang et al., 2019)
	Rakovina vaječníků	E-cadherin	Onkogen	SKOV3, A2780	(Zhou et al., 2017)
	Nemalobuněčný karcinom plic	E-cadherin	Onkogen	A549, NCI-H1299, HCC827	(Wang et al., 2017a)
	Nemalobuněčný karcinom plic	SOX7	Onkogen	A549, HCC827	(Han et al., 2017)
	Rakovina vaječníků	ERK1, ERK2, MMP-9	Tumor supresor	OVCAR3	(He et al., 2017)
	Rakovina žaludku	TNFAIP8	Tumor supresor	MKN-45, MGC-803	(Gao et al., 2017)
	Orální spinocelulární karcinom	CDK6, Cyclin D1	Tumor supresor	Tca8113	(Shang et al., 2017)
	Kolorektální karcinom	TM4SF1	Tumor supresor	SW480, HCT1116	(Park et al., 2016)
	Hepatocelulární karcinom	KLF17	onkogen	HepG2, SMMC7721	(Sun et al., 2013b)
	Karcinom dlaždicovitých buněk jícnu	E-cadherin	Onkogen	KYSE30, KYSE410, KYSE510, HKESC1	(Song et al., 2014b)
	Orální spinocelulární karcinom	CXCR4	Tumor supresor	Tca8113, SCC-9	(Wang, 2014)
	Rakovina děložního čípku (spinocelulární karcinom)	TWIST1	Onkogen	SiHa, CaSki	(Babion et al., 2019)
	Rakovina děložního čípku (adenokarcinom)	TWIST1	Tumor supresor	HeLa	(Babion et al., 2019)
	Rakovina vaječníků	BRCA1	Tumor supresor	C13, OV2008, A2780	(Sun et al., 2013a)
	Osteosarkom	GCIP	Onkogen	HOS, U-2	(Zhu et al., 2015)
	Myeloidní leukemie	RHOH, RYBP	Onkogen		(Chen et al., 2013)
Další rakoviny				(Nowek et al., 2018)	

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-20b-3p	Rakovina děložního čípku		Tumor supresor		(Chen et al., 2020)
	Glioblastom	c-Met	Tumor supresor	LN229, U251,551 W, HG7	(Wu et al., 2019a)
miR-20b-5p	Nádorové buňky	VEGF, HIF-1 $\alpha$	Onkogen	H22, 4T1, RM1, B16	(Lei et al., 2009)
	Rakovina jícnu	PTEN	Onkogen	Eca-109, KYSE-150	(Wang et al., 2016)
	Hepatocelulární karcinom	STAT3	Onkogen	H22	(Luo et al., 2018)
	Rakovina prsu	HIF-1 $\alpha$ , STAT3	Onkogen	MCF-7	(Cascio et al., 2010)
	Rakovina prsu	CCND1, E2F1	Onkogen	MCF-7, T47D	(Xia et al., 2020)
	Hepatocelulární karcinom	HIF-1 $\alpha$ , VEGF	Onkogen	HepG2	(Xue et al., 2015)
	Folikulární lymfom	CDKN1A	Onkogen	OCI-Ly8	(Wang et al., 2012)
	Rakovina prostaty	PTEN	Onkogen	VCaP, PC-3	(Guo et al., 2017b)
	Rakovina prsu	PTEN	Onkogen	ZR-75-30, MCF-7	(Zhou et al., 2014)
	Kolorektální karcinom	PTEN		CHO	(Zhu et al., 2014)
	Nemalobuněčný karcinom plic	APC	Onkogen	PC-9, H1975, H1299, A549	(Ren et al., 2020)
	Rakovina děložního čípku	TIMP-2	onkogen	C33A, HeLa, SiHa, Caski	(Cheng et al., 2017)
miR-199a-3p	Kožní spinocelulární karcinom	CD44	Tumor supresor	A-431	(Wang et al., 2014b)
	Rakovina žaludku	ZHX1	Onkogen	AGS, MKN-45, MKN-028, SGC-7901, NCI-N87	(Wang et al., 2014c)
	Rakovina prsu	Kaveolin-2	Onkogen	YPEN-1, MT-1, MDA-MB-231	(Shatseva et al., 2011)
	Rakovina vaječníků	IKK $\beta$	Tumor supresor	SKOV3, A2780, CP70	(Chen et al., 2008)
	Rakovina žaludku	mTOR	Tumor represor	AGS, SGC-7901	(Peng et al., 2013)
	Hepatocelulární karcinom	mTOR	Tumor supresor		(Varshney et al., 2018)
	Hepatocelulární karcinom	PDCD4	Tumor supresor	HL-7702, BNL CL.2	(Li et al., 2020b)
	Nemalobuněčný karcinom plic	ZEB1	Tumor supresor	A549	(Bai and Jiao, 2020)



miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-199a-3p	Rakovina prsu		Tumor supresor	HCC1806, HCC1937, MDA-MB-231	(Huang et al., 2020)
	Osteosarkom	mTOR	Tumor supresor	HOB-c, NHOST, hFOB	(Duan et al., 2011)
	Rakovina jícnu	AK4	Onkogen	Kyse 30-R, Kyse 150-R	(Zang et al., 2018)
	Osteosarkom	AK4	Onkogen	G-292, U2OS	(Lei et al., 2018)
	Rakovina jícnu	PAK4	Tumor supresor	TE7, TE10, FLO1	(Phatak et al., 2018)
	Hepatocelulární karcinom	mTOR, PAK4	Tumor supresor	Hep3B, HepG2	(Callegari et al., 2018)
	Hepatocelulární karcinom	VEGFA, VEGFR1, VEGFR2, HGF, MMP2	Tumor supresor	HepG2, SNU449	(Ghosh et al., 2017)
	Rakovina vaječnicků	c-MET	Tumor supresor	SKOV3ip1, CaOV3, RMUG-S, SKOV-3-13	(Kinose et al., 2015)
	Rakovina prostaty	Smad1	Tumor supresor	PC-3	(Qu et al., 2017)
	Rakovina štítné žlázy	MET, mTOR	Tumor supresor	TPC1, NIM-1, K1	(Minna et al., 2014)
mi-21-3p	Rakovina endometria	L1CAM	Onkogen	EFE124, MFE 296, EN1	(Doberstein et al., 2014)
	Renální rakovina	L1CAM	Onkogen	A498, 786-0, HK2	(Doberstein et al., 2014)
	Rakovina vaječnicků	L1CAM	Onkogen	OVM	(Doberstein et al., 2014)
	Hepatocelulární karcinom	MAT2A, MAT2B	Tumor supresor	HepG2	(Lo et al., 2013)
	Kolorektální karcinom	SMAD7	Onkogen	HCT116, SW480	(Jiao et al., 2017)
	Rakovina jater	PTEN	Tumor supresor	Huh7	(Zhu et al., 2019)
	Rakovina vaječnicků a prosty	RBPMS, RCBTB1, ZNF608	Onkogen	A2780CP20, SKOV3ip1, PC3	(Báez-Vega et al., 2016)
	Melanom	TAP1	Onkogen	BUF1379, FM3, FM81	(Lazaridou et al., 2020)
miR-139-5p	Rakovina slinivky	EZH2	Tumor supresor	SW1990, BxPC-3	(Ma et al., 2018)
	Rakovina vaječnicků	ROCK1	Tumor supresor	SKOV3, A2780, OVCAR, HO-8910, HOSEpiC	(Wang et al., 2018b)
	Nemalobuněčný karcinom plic	c-Met	Tumor supresor	A549, SK-MES-1	(Sun et al., 2015)

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-139-5p	Rakovina tlustého střeva	NOTCH1	Tumor supresor	DLD1, HCT116, SW1116	(Zhang et al., 2014)
	Hepatocelulární karcinom	ROCK2	Tumor supresor	SMMC-7721, BEL7402	(Wong et al., 2011)
	Glioblastom	Notch1	Tumor supresor	LN229, U87	(Li et al., 2018)
	Kolorektální karcinom	BCL2	Tumor supresor	HCT116, SW620	(Li et al., 2016a)
	Rakovina endometria	HOXA10	Tumor supresor	ECC1, Ishikawa	(Liu et al., 2018)
	Glioblastom	Ftl1	Tumor supresor	U87, LN229	(Wang et al., 2018a)
	Orální spinocelulární karcinom	HOXA9	Tumor supresor	SAS, CAL-27	(Wang et al., 2017b)
	Rakovina močového měchýře	MMP11	Tumor supresor	T24, BOY	(Yonemori et al., 2016)
	Glioblastom	Mcl-1	Tumor supresor	U87, LN229	(Li et al., 2013)
	Hepatocelulární karcinom	SLITRK4	Tumor supresor	SK-HEP-1, HA22T	(Wu et al., 2020a)
	Rakovina prostaty	IGF1R, AXL	Tumor supresor	PC3, Du145	(Nam et al., 2019)
	Rakovina jícnu	VEGF	Tumor supresor	KYSE 150	(Jiao et al., 2019)
	Osteosarkom	DNMT1	Tumor supresor	MG63, U2OS	(Shi and Guo, 2018)
	Nemalobuněčný karcinom plic	IGF1R	Tumor supresor	A549, SK-MES-1, H520	(Xu et al., 2015b)
	Kolorektální karcinom	AMFR, NOTCH1	Tumor supresor	HCT-116, LoVo	(Song et al., 2014a)
	Rakovina jícnu	NR5A2	Tumor supresor	EC109, EC9706, CaEs-17, KYSE150, TE1	(Liu et al., 2013a)
	Rakovina žaludku	PMP22	Tumor supresor	SGC7901, BGC823	(Hou et al., 2020)
	Nemalobuněčný karcinom plic	HDGF	Tumor supresor	A549, H1299	(Zhang et al., 2020)
	Hemangion	IGF-1R	Tumor supresor	HemSCs	(Wu et al., 2020b)
	Rakovina močového měchýře	CX43	Tumor supresor	ECV-304	(Chi et al., 2019)
Rakovina děložního čípku	TCF4	Tumor supresor	CaSki, SiHa, Hela, C-33A	(Ji et al., 2019)	
Pankreatický duktální adenokarcinom	Thymopoietin	Tumor supresor	SW1990, ASPC-1, BXP-3, PANC-1	(Zhou et al., 2019)	

miRNA	Druh rakoviny/nádoru	Cílový gen	Funkční role miR	Buňky	Zdroj
miR-139-5p	Hepatocelulární karcinom	SPOCK1	Tumor supresor	HepG2, Hep3b	(Li et al., 2019a)
miR-663a	Rakovina tlustého střeva	TTC22	Tumor supresor	HCT116, SW480	(Tian et al., 2019)
	Melanom	FHL3	Onkogen	A375, WM451	(Liu et al., 2020b)
	Glioblastom	TGF- $\beta$ 1	Tumor supresor	A172 a U87	(Li et al., 2016b)
	Hepatocelulární karcinom	TGF- $\beta$ 1	Tumor supresor	SK-HEP1, Huh-7	(Zhang et al., 2018a)
	Rakovina tlustého střeva	CXCR4	Tumor supresor	HCT116	(Kuroda et al., 2017)
	Nemalobuněčný karcinom plic	JunD	Tumor supresor	H460, H1299	(Zhang et al., 2016b)
	Nasofaryngeální karcinom	CDKN2A	Onkogen	C666-1	(Liang et al., 2017)
	Rakovina vaječníků	TUSC2	Onkogen	SKOV3	(Xie et al., 2019)

Agirre, X., Jiménez-Velasco, A., San José-Enériz, E., Garate, L., Bandrés, E., Cordeu, L., Aparicio, O., Saez, B., Navarro, G., Vilas-Zornoza, A., et al. (2008). Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. *Mol. Cancer Res.* 6, 1830–1840.

Arora, H., Qureshi, R., Jin, S., Park, A.K., and Park, W.Y. (2011). MiR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NF $\kappa$ B1. *Exp. Mol. Med.* 43, 298–304.

Babion, I., Jaspers, A., van Splunter, A.P., van der Hoorn, I.A.E., Wilting, S.M., and Steenbergen, R.D.M. (2019). miR-9-5p Exerts a Dual Role in Cervical Cancer and Targets Transcription Factor TWIST1. *Cells* 9.

Báez-Vega, P.M., Vargas, I.M.E., Valiyeva, F., Rosado, J.E., Roman, A., Flores, J., Marcos-Martínez, M.J., and Vivas-Mejía, P.E. (2016). Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. *Oncotarget* 7, 36321–36337.

Bai, J., and Jiao, W.Y. (2020). Down-regulation of ZEB1 by miR-199a-3p overexpression restrains tumor stem-like properties and mitochondrial function of non-small cell lung cancer. *Onco. Targets. Ther.* 13, 4607–4616.

Bandres, E., Bitarte, N., Arias, F., Agorreta, J., Fortes, P., Agirre, X., Zarate, R., Diaz-Gonzalez, J.A., Ramirez, N., Sola, J.J., et al. (2009). microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. *Clin. Cancer Res.* 15, 2281–2290.

Callegari, E., D'Abundo, L., Guerriero, P., Simioni, C., Elamin, B.K., Russo, M., Cani, A., Bassi, C., Zagatti, B., Giacomelli, L., et al. (2018). miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. *Mol. Ther. - Nucleic Acids* 11, 485–493.

- Cao, X.-C., Yu, Y., Hou, L.-K., Sun, X.-H., Ge, J., Zhang, B., and Wang, X. (2016). miR-142-3p inhibits cancer cell proliferation by targeting CDC25C. *Cell Prolif.* *49*, 58–68.
- Cascio, S., D'Andrea, A., Ferla, R., Surmacz, E., Gulotta, E., Amodeo, V., Bazan, V., Gebbia, N., and Russo, A. (2010). miR-20b modulates VEGF expression by targeting HIF-1 $\alpha$  and STAT3 in MCF-7 breast cancer cells. *J. Cell. Physiol.* *224*, n/a-n/a.
- Chai, S., Tong, M., Ng, K.Y., Kwan, P.S., Chan, Y.P., Fung, T.M., Lee, T.K., Wong, N., Xie, D., Yuan, Y.F., et al. (2014). Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. *Oncotarget* *5*, 5725–5735.
- Chen, J., and Chen, X. (2018). MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis. *Oncol. Res.* *26*, 913–922.
- Chen, G.M., Zheng, A.J., Cai, J., Han, P., Ji, H.B., and Wang, L. Le (2018). microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway. *J. Cell. Biochem.* *119*, 885–895.
- Chen, L., Hu, W., Li, G., Guo, Y., Wan, Z., and Yu, J. (2019a). Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. *Cell. Mol. Biol. Lett.* *24*.
- Chen, P., Price, C., Li, Z., Li, Y., Cao, D., Wiley, A., He, C., Gurbuxani, S., Kunjamma, R.B., Huang, H., et al. (2013). miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. *Proc. Natl. Acad. Sci. U. S. A.* *110*, 11511–11516.
- Chen, P., Zhang, W., Chen, Y., Zheng, X., and Yang, D. (2020). Comprehensive analysis of aberrantly expressed long non-coding RNAs, microRNAs, and mRNAs associated with the competitive endogenous RNA network in cervical cancer. *Mol. Med. Rep.* *22*, 405–415.
- Chen, R., Alvero, A.B., Silasi, D.A., Kelly, M.G., Fest, S., Visintin, I., Leiser, A., Schwartz, P.E., Rutherford, T., and Mor, G. (2008). Regulation of IKK $\beta$  by miR-199a affects NF- $\kappa$ B activity in ovarian cancer cells. *Oncogene* *27*, 4712–4723.
- Chen, S., Zhang, J.Y., Sun, L.S., Li, X.F., Bai, J.Y., Zhang, H.Y., and Li, T.J. (2019b). miR-762 promotes malignant development of head and neck squamous cell carcinoma by targeting PHLPP2 and FOXO4. *Onco. Targets. Ther.* *12*, 11425–11436.
- Chen, X. nan, Wang, K. feng, Xu, Z. qun, Li, S. jie, Liu, Q., Fu, D. hui, Wang, X., and Wu, B. (2014). MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. *Cancer Cell Int.* *14*, 70.
- Cheng, Y., Geng, L., Zhao, L., Zuo, P., and Wang, J. (2017). Human papillomavirus E6-regulated microRNA-20b promotes invasion in cervical cancer by targeting tissue inhibitor of metalloproteinase 2. *Mol. Med. Rep.* *16*, 5464–5470.
- Chi, Q., Wang, Z.Y., Li, H.Y., Song, D. Bin, Xu, H., Ma, G., Wang, Z.M., and Li, X.M. (2019). Tumor-suppressor microRNA-139-5p restrains bladder cancer cell line ECV-304 properties via targeting Connexin 43. *Chin. Med. J. (Engl.)* *132*, 2354–2361.
- Crawford, M., Batte, K., Yu, L., Wu, X., Nuovo, G.J., Marsh, C.B., Otterson, G.A., and Nana-Sinkam, S.P. (2009). MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. *Biochem. Biophys. Res. Commun.* *388*, 483–489.

- Cui, S., Yang, X., Zhang, L., Zhao, Y., and Yan, W. (2018). LncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. *Biochem. Biophys. Res. Commun.* *506*, 251–258.
- Cui, W., Zhang, S., Shan, C., Zhou, L., and Zhou, Z. (2013). MicroRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. *FEBS J.* *280*, 3962–3974.
- Deng, B., Zhang, Y., Zhang, S., Wen, F., Miao, Y., and Guo, K. (2015). MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. *Tumor Biol.* *36*, 8065–8073.
- Doberstein, K., Bretz, N.P., Schirmer, U., Fiegl, H., Blaheta, R., Breunig, C., Müller-Holzner, E., Reimer, D., Zeimet, A.G., and Altevogt, P. (2014). MiR-21-3p is a positive regulator of L1CAM in several human carcinomas. *Cancer Lett.* *354*, 455–466.
- Dou, L., Li, J., Zheng, D., Li, Y., Gao, X., Xu, C., Gao, L., Wang, L., and Yu, L. (2013). MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene. *Mol. Biol. Rep.* *40*, 6811–6819.
- Duan, Z., Choy, E., Harmon, D., Liu, X., Susa, M., Mankin, H., and Hornicek, F. (2011). MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. *Mol. Cancer Ther.* *10*, 1337–1345.
- Eades, G., Wolfson, B., Zhang, Y., Li, Q., Yao, Y., and Zhou, Q. (2015). LincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting Arf6. *Mol. Cancer Res.* *13*, 330–338.
- Farooqi, A.A., ur Rehman, Z., and Muntane, J. (2014). Antisense therapeutics in oncology: Current status. *Onco. Targets. Ther.* *7*, 2035–2042.
- Feng, Y., Zhu, J., Ou, C., Deng, Z., Chen, M., Huang, W., and Li, L. (2014). MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. *Br. J. Cancer* *110*, 2300–2309.
- Fukumoto, I., Kinoshita, T., Hanazawa, T., Kikkawa, N., Chiyomaru, T., Enokida, H., Yamamoto, N., Goto, Y., Nishikawa, R., Nakagawa, M., et al. (2014). Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. *Br. J. Cancer* *111*, 386–394.
- Gao, G., Gay, H.A., Chernock, R.D., Zhang, T.R., Luo, J., Thorstad, W.L., Lewis, J.S., and Wang, X. (2013). A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. *Cancer* *119*, 72–80.
- Gao, H.Y., Huo, F.C., Wang, H.Y., and Pei, D.S. (2017). MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8. *Cell Prolif.* *50*.
- Ge, P., Cao, L., Chen, X., Jing, R., and Yue, W. (2019). MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. *BMC Cancer* *19*.

- Ghosh, A., Dasgupta, D., Ghosh, A., Roychoudhury, S., Kumar, D., Gorain, M., Butti, R., Datta, S., Agarwal, S., Gupta, S., et al. (2017). MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. *Cell Death Dis.* *8*, e2706.
- Gómez-Gómez, Y., Organista-Nava, J., Ocadiz-Delgado, R., García-Villa, E., Leyva-Vazquez, M.A., Illades-Aguilar, B., Lambert, P.F., García-Carrancá, A., and Gariglio, P. (2016). The expression of miR-21 and miR-143 is deregulated by the HPV16 E7 oncoprotein and 17-estradiol. *Int. J. Oncol.* *49*, 549–558.
- Goto, Y., Kurozumi, A., Arai, T., Nohata, N., Kojima, S., Okato, A., Kato, M., Yamazaki, K., Ishida, Y., Naya, Y., et al. (2017). Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. *Br. J. Cancer* *117*, 409–420.
- Guo, D., Ma, J., Yan, L., Li, T., Li, Z., Han, X., and Shui, S. (2017a). Down-Regulation of Lncrna MALAT1 Attenuates Neuronal Cell Death Through Suppressing Beclin1-Dependent Autophagy by Regulating Mir-30a in Cerebral Ischemic Stroke. *Cell. Physiol. Biochem.* *43*, 182–194.
- Guo, F., Hou, X., and Sun, Q. (2018). microRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF. *Oncol. Lett.* *16*, 6815–6821.
- Guo, J., Xia, B., Meng, F., and Lou, G. (2014). miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. *Tumor Biol.* *35*, 1557–1564.
- Guo, J., Xiao, Z., Yu, X., and Cao, R. (2017b). miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer. *Oncol. Lett.* *14*, 6895–6900.
- Han, L., Wang, W., Ding, W., and Zhang, L. (2017). MiR-9 is involved in TGF- $\beta$ 1-induced lung cancer cell invasion and adhesion by targeting SOX7. *J. Cell. Mol. Med.* *21*, 2000–2008.
- He, L., Zhang, L., Wang, M., and Wang, W. (2017). miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1/CXCR4 pathway. *Exp. Ther. Med.* *13*, 1203–1208.
- He, Z., Yi, J., Liu, X., Chen, J., Han, S., Jin, L., Chen, L., and Song, H. (2016). MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. *Mol. Cancer* *15*, 51.
- Hou, J., Zhuo, H., Chen, X., Cheng, J., Zheng, W., Zhong, M., and Cai, J.C. (2020). MiR-139-5p negatively regulates pmp22 to repress cell proliferation by targeting the nf-kb signaling pathway in gastric cancer. *Int. J. Biol. Sci.* *16*, 1218–1229.
- Hou, R., Yang, Z., Wang, S., Chu, D., Liu, Q., Liu, J., and Jiang, L. (2017). miR-762 can negatively regulate menin in ovarian cancer. *Onco. Targets. Ther.* *10*, 2127–2137.
- Hu, G., Chen, D., Li, X., Yang, K., Wang, H., and Wu, W. (2010). miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. *Cancer Biol. Ther.* *10*, 190–197.

Hu, X., Liu, W., Jiang, X., Wang, B., Li, L., Wang, J., and Ma, J. (2019). Long noncoding RNA LINC00460 aggravates invasion and metastasis by targeting miR-30a-3p/Rap1A in nasopharyngeal carcinoma. *Hum. Cell* 32, 465–476.

Hua, S., Liu, C., Liu, L., and Wu, D. (2018). miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. *Biochem. Biophys. Res. Commun.* 496, 947–954.

Huang, R., Li, J., Pan, F., Zhang, B., and Yao, Y. (2020). The activation of GPER inhibits cells proliferation, invasion and EMT of triple-negative breast cancer via CD151/miR-199a-3p bio-axis. *Am. J. Transl. Res.* 12, 32–44.

Ji, X., Guo, H., Yin, S., and Du, H. (2019). MiR-139-5p functions as a tumor suppressor in cervical cancer by targeting TCF4 and inhibiting Wnt/ $\beta$ -catenin signalling. *Onco. Targets. Ther.* 12, 7739–7748.

Jia, H., Zhang, Z., Zou, D., Wang, B., Yan, Y., Luo, M., Dong, L., Yin, H., Gong, B., Li, Z., et al. (2014). MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. *PLoS One* 9.

Jiao, W., Leng, X., Zhou, Q., Wu, Y., Sun, L., Tan, Y., Ni, H., Dong, X., Shen, T., Liu, Y., et al. (2017). Different miR-21-3p isoforms and their different features in colorectal cancer. *Int. J. Cancer* 141, 2103–2111.

Jiao, W., Zhang, J., Wei, Y., Feng, J., Ma, M., Zhao, H., Wang, L., and Jiao, W. (2019). MiR-139-5p regulates VEGFR and downstream signaling pathways to inhibit the development of esophageal cancer. *Dig. Liver Dis.* 51, 149–156.

Kano, M., Seki, N., Kikkawa, N., Fujimura, L., Hoshino, I., Akutsu, Y., Chiyomaru, T., Enokida, H., Nakagawa, M., and Matsubara, H. (2010). MiR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. *Int. J. Cancer* 127, 2804–2814.

Kinose, Y., Sawada, K., Nakamura, K., Sawada, I., Toda, A., Nakatsuka, E., Hashimoto, K., Mabuchi, S., Takahashi, K., Kurachi, H., et al. (2015). The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. *Oncotarget* 6, 11342–11356.

Kleemann, M., Bereuther, J., Fischer, S., Marquart, K., Hänle, S., Unger, K., Jendrossek, V., Riedel, C.U., Handrick, R., and Otte, K. (2017). Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis. *Oncotarget* 8, 18773–18791.

Kojima, S., Chiyomaru, T., Kawakami, K., Yoshino, H., Enokida, H., Nohata, N., Fuse, M., Ichikawa, T., Naya, Y., Nakagawa, M., et al. (2012). Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. *Br. J. Cancer* 106, 405–413.

Kuroda, K., Fukuda, T., Krstic-Demonacos, M., Demonacos, C., Okumura, K., Isogai, H., Hayashi, M., Saito, K., and Isogai, E. (2017). miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway. *BMC Cancer* 17, 33.

Lazaridou, M.-F., Massa, C., Handke, D., Mueller, A., Friedrich, M., Subbarayan, K., Tretbar, S., Dummer, R., Koelblinger, P., and Seliger, B. (2020). Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. *J. Clin. Med.* 9, 2690.

- Lee, C.G., McCarthy, S., Gruidl, M., Timme, C., and Yeatman, T.J. (2014). MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. *PLoS One* 9.
- Lei, W., Yan, C., Ya, J., Yong, D., Yujun, B., and Kai, L. (2018). MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. *BMC Cancer* 18, 631.
- Lei, Z., Li, B., Yang, Z., Fang, H., Zhang, G.M., Feng, Z.H., and Huang, B. (2009). Regulation of HIF-1 $\alpha$  and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. *PLoS One* 4.
- Li, J., Li, Q., Lin, L., Wang, R., Chen, L., Du, W., Jiang, C., and Li, R. (2018). Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT). *BMC Neurol.* 18, 133.
- Li, J., Zhang, S., Zou, Y., Wu, L., Pei, M., and Jiang, Y. (2020a). miR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells. *J. Cell. Physiol.* 235, 4291–4301.
- Li, P., Xiao, Z., Luo, J., Zhang, Y., and Lin, L. (2019a). MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1. *J. Cell. Mol. Med.* 23, 2475–2488.
- Li, Q., Liang, X., Wang, Y., Meng, X., Xu, Y., Cai, S., Wang, Z., Liu, J., and Cai, G. (2016a). MiR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2. *Sci. Rep.* 6.
- Li, Q., Cheng, Q., Chen, Z., Peng, R., Chen, R., Ma, Z., Wan, X., Liu, J., Meng, M., Peng, Z., et al. (2016b). MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-1. *Oncol. Rep.* 35, 1125–1134.
- Li, Q., Yu, X., and Yang, L. (2019b). MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt/ $\beta$ -catenin pathway. *Int. J. Clin. Exp. Pathol.* 12, 3740–3751.
- Li, R.Y., Chen, L.C., Zhang, H.Y., Du, W.Z., Feng, Y., Wang, H.B., Wen, J.Q., Liu, X., Li, X.F., Sun, Y., et al. (2013). MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. *CNS Neurosci. Ther.* 19, 477–483.
- Li, Y., Huang, R., Wang, L., Hao, J., Zhang, Q., Ling, R., and Yun, J. (2015a). microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression. *Cell Prolif.* 48, 643–649.
- Li, Y., Wang, J., Dai, X., Zhou, Z., Liu, J., Zhang, Y., Li, Y., Hou, Y., Pang, L., Wang, X., et al. (2015b). miR-451 regulates FoxO3 nuclear accumulation through Ywhaz in human colorectal cancer (e-Century Publishing Corporation).
- Li, Z., Zhou, Y., Zhang, L., Jia, K., Wang, S., Wang, M., Li, N., Yu, Y., Cao, X., and Hou, J. (2020b). microRNA-199a-3p inhibits hepatic apoptosis and hepatocarcinogenesis by targeting PDCD4. *Oncogenesis* 9, 95.
- Liang, S., Zhang, N., Deng, Y., Chen, L., Zhang, Y., Zheng, Z., Luo, W., Lv, Z., Li, S., and Xu, T. (2017). MiR-663 promotes NPC cell proliferation by directly targeting CDKN2A. *Mol. Med. Rep.* 16, 4863–4870.



- Liu, G., Li, Y., and Gao, X. (2016). Overexpression of microRNA-133b sensitizes non-small cell lung cancer cells to irradiation through the inhibition of glycolysis. *Oncol. Lett.* *11*, 2903–2908.
- Liu, J., Li, C., Jiang, Y., Wan, Y., Zhou, S., and Cheng, W. (2018). Tumor-suppressor role of miR-139-5p in endometrial cancer. *Cancer Cell Int.* *18*, 51.
- Liu, N., Bezprozvannaya, S., Williams, A.H., Qi, X., Richardson, J.A., Bassel-Duby, R., and Olson, E.N. (2008). microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. *Genes Dev.* *22*, 3242–3254.
- Liu, R., Yang, M., Meng, Y., Liao, J., Sheng, J., Pu, Y., Yin, L., and Kim, S.J. (2013a). Tumor-Suppressive Function of miR-139-5p in Esophageal Squamous Cell Carcinoma. *PLoS One* *8*.
- Liu, S., Sun, J., and Lan, Q. (2013b). TGF- $\beta$ -induced miR10a/b expression promotes human glioma cell migration by targeting PTEN. *Mol. Med. Rep.* *8*, 1741–1746.
- Liu, S., Li, S., Yu, X., Wang, Q., and Sun, H. (2020a). microRNA-133b represses the progression of lung cancer through inhibiting SOX9/ $\beta$ -catenin signaling pathway. *Int. J. Clin. Exp. Pathol.* *13*, 2270–2279.
- Liu, S., Hu, Y., Wu, S., He, Y., and Deng, L. (2020b). MicroRNA-663 Regulates Melanoma Progression by Inhibiting FHL3. *Technol. Cancer Res. Treat.* *19*.
- Liu, T., Lu, Q., Liu, J., Xie, S., Feng, B., Zhu, W., Liu, M., Liu, Y., Zhou, X., Sun, W., et al. (2020c). Circular RNA FAM114A2 suppresses progression of bladder cancer via regulating  $\Delta$ NP63 by sponging miR-762. *Cell Death Dis.* *11*, 47.
- Liu, X., Ji, Q., Zhang, C., Liu, X., Liu, Y., Liu, N., Sui, H., Zhou, L., Wang, S., and Li, Q. (2017a). MIR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. Pylori gastric cancer models. *Sci. Rep.* *7*.
- Liu, Y., Zhang, Y., Wu, H., Li, Y., Zhang, Y., Liu, M., Li, X., and Tang, H. (2017b). MiR-10a suppresses colorectal cancer metastasis by modulating the epithelial-To-mesenchymal transition and anoikis. *Cell Death Dis.* *8*.
- Lo, T.-F., Tsai, W.-C., and Chen, S.-T. (2013). MicroRNA-21-3p, a Berberine-Induced miRNA, Directly Down-Regulates Human Methionine Adenosyltransferases 2A and 2B and Inhibits Hepatoma Cell Growth. *PLoS One* *8*, e75628.
- Long, M.J., Wu, F.X., Li, P., Liu, M., Li, X., and Tang, H. (2012). MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. *Cancer Lett.* *324*, 186–196.
- Luo, Y., He, J., Tao, X., Wang, H., Fang, Q., Guo, S., and Song, C. (2018). miR-20b negatively regulates VEGF expression by targeting STAT3 in H22 hepatocellular carcinoma cells. *Oncol. Rep.* *40*, 2806–2813.
- Lv, M., Zhang, X., Jia, H., Li, D., Zhang, B., Zhang, H., Hong, M., Jiang, T., Jiang, Q., Lu, J., et al. (2012). An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor- $\alpha$  and cAMP/PKA pathways. *Leukemia* *26*, 769–777.

- Ma, J., Zhang, J., Weng, Y.C., and Wang, J.C. (2018). EZH2-mediated microRNA-139-5p regulates epithelial-mesenchymal transition and lymph node metastasis of pancreatic cancer. *Mol. Cells* *41*, 868–880.
- MacKenzie, T.N., Mujumdar, N., Banerjee, S., Sangwan, V., Sarver, A., Vickers, S., Subramanian, S., and Saluja, A.K. (2013). Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. *Mol. Cancer Ther.* *12*, 1266–1275.
- Mataki, H., Seki, N., Mizuno, K., Nohata, N., Kamikawaji, K., Kumamoto, T., Koshizuka, K., Goto, Y., and Inoue, H. (2016). Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. *Oncotarget* *7*, 72084–72098.
- Mathew, L.K., Lee, S.S., Skuli, N., Rao, S., Keith, B., Nathanson, K.L., Lal, P., and Simon, M.C. (2014). Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2 $\alpha$  activity. *Cancer Discov.* *4*, 53–60.
- Matsushita, R., Yoshino, H., Enokida, H., Goto, Y., Miyamoto, K., Yonemori, M., Inoguchi, S., Nakagawa, M., and Seki, N. (2016). Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR 145-3p): Inhibition of bladder cancer cell aggressiveness. *Oncotarget* *7*, 28460–28487.
- Minna, E., Romeo, P., De Cecco, L., Dugo, M., Cassinelli, G., Pilotti, S., Degl’Innocenti, D., Lanzi, C., Casalini, P., Pierotti, M.A., et al. (2014). miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. *Oncotarget* *5*, 2513–2528.
- Minna, E., Romeo, P., Dugo, M., De Cecco, L., Todoerti, K., Pilotti, S., Perrone, F., Seregini, E., Agnelli, L., Neri, A., et al. (2016). miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. *Oncotarget* *7*, 12731–12747.
- Misono, S., Seki, N., Mizuno, K., Yamada, Y., Uchida, A., Arai, T., Kumamoto, T., Sanada, H., Suetsugu, T., and Inoue, H. (2018). Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis. *J. Hum. Genet.* *63*, 1015–1028.
- Nam, R.K., Benatar, T., Wallis, C.J.D., Kobylecky, E., Amemiya, Y., Sherman, C., and Seth, A. (2019). MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. *Prostate* *79*, 1435–1451.
- Nan, Y., Han, L., Zhang, A., Wang, G., Jia, Z., Yang, Y., Yue, X., Pu, P., Zhong, Y., and Kang, C. (2010). MiRNA-451 plays a role as tumor suppressor in human glioma cells. *Brain Res.* *1359*, 14–21.
- Ng, E.K.O., Tsang, W.P., Ng, S.S.M., Jin, H.C., Yu, J., Li, J.J., Röcken, C., Ebert, M.P.A., Kwok, T.T., and Sung, J.J.Y. (2009). MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. *Br. J. Cancer* *101*, 699–706.
- Nowek, K., Wiemer, E.A.C., and Jongen-Lavrencic, M. (2018). The versatile nature of miR-9/9\* in human cancer. *Oncotarget* *9*, 20838–20854.

- Ovcharenko, D., Stölzel, F., Poitz, D., Fierro, F., Schaich, M., Neubauer, A., Kelnar, K., Davison, T., Müller-Tidow, C., Thiede, C., et al. (2011). Mir-10a overexpression is associated with *npm1* mutations and *mdm4* downregulation in intermediate-risk acute myeloid leukemia. *Exp. Hematol.* *39*, 1030-1042.e7.
- Park, Y.R., Lee, S.T., Kim, S.L., Liu, Y.C., Lee, M.R., Shin, J.H., Seo, S.Y., Kim, S.H., Kim, I.H., Lee, S.O., et al. (2016). MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. *Int. J. Oncol.* *48*, 2135–2143.
- Peng, W., Chen, Z.Y., Wang, L., Wang, Z., and Li, J. (2013). MicroRNA-199a-3p is downregulated in gastric carcinomas and modulates cell proliferation. *Genet. Mol. Res.* *12*, 3038–3047.
- Peschiaroli, A., Giacobbe, A., Formosa, A., Markert, E.K., Bongiorno-Borbone, L., Levine, A.J., Candi, E., D'Alessandro, A., Zolla, L., Finazzi Agrò, A., et al. (2013). MiR-143 regulates hexokinase 2 expression in cancer cells. *Oncogene* *32*, 797–802.
- Phatak, P., Burrows, W.M., Chesnick, I.E., Tulapurkar, M.E., Rao, J.N., Turner, D.J., Hamburger, A.W., Wang, J.Y., and Donahue, J.M. (2018). MiR-199a-3p decreases esophageal cancer cell proliferation by targeting p21 activated kinase 4. *Oncotarget* *9*, 28391–28407.
- Qi, B., Wang, Y., Chen, Z.J., Li, X.N., Qi, Y., Yang, Y., Cui, G.H., Guo, H.Z., Li, W.H., and Zhao, S. (2017). Down-regulation of miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway. *World J. Gastroenterol.* *23*, 7965–7977.
- Qi, X., Li, J., Zhou, C., Lv, C., and Tian, M. (2015). MiR-142-3p Suppresses SOCS6 Expression and Promotes Cell Proliferation in Nasopharyngeal Carcinoma. *Cell. Physiol. Biochem.* *36*, 1743–1752.
- Qin, W., Dong, P., Ma, C., Mitchelson, K., Deng, T., Zhang, L., Sun, Y., Feng, X., Ding, Y., Lu, X., et al. (2012). MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. *Oncogene* *31*, 4067–4075.
- Qu, F., Zheng, J., Gan, W., Lian, H., He, H., Li, W., Yuan, T., Yang, Y., Li, X., Ji, C., et al. (2017). MiR-199a-3p suppresses proliferation and invasion of prostate cancer cells by targeting Smad1. *Oncotarget* *8*, 52465–52473.
- Ren, T., Fan, X.X., Wang, M.F., Duan, F.G., Wei, C.L., Li, R.Z., Jiang, Z.B., Wang, Y.W., Yao, X.J., Chen, M.W., et al. (2020). MiR-20b promotes growth of non-small cell lung cancer through a positive feedback loop of the Wnt/ $\beta$ -catenin signaling pathway. *Int. J. Oncol.* *56*, 470–479.
- Riquelme, I., Tapia, O., Leal, P., Sandoval, A., Varga, M.G., Letelier, P., Buchegger, K., Bizama, C., Espinoza, J.A., Peek, R.M., et al. (2016). miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. *Cell. Oncol.* *39*, 23–33.
- Ruhl, R., Rana, S., Kelley, K., Espinosa-Diez, C., Hudson, C., Lanciault, C., Thomas, C.R., Liana Tsikitis, V., and Anand, S. (2018). microRNA-451a regulates colorectal cancer proliferation in response to radiation. *BMC Cancer* *18*, 517.
- Sathyanarayanan, A., Chandrasekaran, K.S., and Karunakaran, D. (2018). microRNA-145 downregulates SIP1-expression but differentially regulates proliferation, migration, invasion and Wnt signaling in SW480 and SW620 cells. *J. Cell. Biochem.* *119*, 2022–2035.

- Shang, A., Lu, W.-Y., Yang, M., Zhou, C., Zhang, H., Cai, Z.-X., Wang, W.-W., Wang, W.-X., and Wu, G.-Q. (2017). miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway. *Artif. Cells, Nanomedicine, Biotechnol.* *46*, 1–9.
- Shatseva, T., Lee, D.Y., Deng, Z., and Yang, B.B. (2011). MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. *J. Cell Sci.* *124*, 2826–2836.
- Shen, W.W., Zeng, Z., Zhu, W.X., and Fu, G.H. (2013). MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. *J. Mol. Med.* *91*, 989–1000.
- Sheng, N., Tan, G., You, W., Chen, H., Gong, J., Chen, D., Zhang, H., and Wang, Z. (2017). MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway. *Cancer Med.* *6*, 1331–1340.
- Shi, Y.K., and Guo, Y.H. (2018). MiR-139-5p suppresses osteosarcoma cell growth and invasion through regulating DNMT1. *Biochem. Biophys. Res. Commun.* *503*, 459–466.
- Shi, B., Sepp-Lorenzino, L., Prisco, M., Linsley, P., Deangelis, T., and Baserga, R. (2007). Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. *J. Biol. Chem.* *282*, 32582–32590.
- Shi, H., Shen, H., Xu, J., Zhao, S., Yao, S., and Jiang, N. (2018). MiR-143-3p suppresses the progression of ovarian cancer. *Am. J. Transl. Res.* *10*, 866–874.
- Shi, M., Du, L., Liu, D., Qian, L., Hu, M., Yu, M., Yang, Z., Zhao, M., Chen, C., Guo, L., et al. (2012). Glucocorticoid regulation of a novel HPV-E6-p53- **miR-145** pathway modulates invasion and therapy resistance of cervical cancer cells. *J. Pathol.* *228*, 148–157.
- Shiah, S.G., Hsiao, J.R., Chang, H.J., Hsu, Y.M., Wu, G.H., Peng, H.Y., Chou, S.T., Kuo, C.C., and Chang, J.Y. (2020). MiR-30a and miR-379 modulate retinoic acid pathway by targeting DNA methyltransferase 3B in oral cancer. *J. Biomed. Sci.* *27*.
- Shimonosono, M., Idichi, T., Seki, N., Yamada, Y., Arai, T., Arigami, T., Sasaki, K., Omoto, I., Uchikado, Y., Kita, Y., et al. (2019). Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR-145-3p on gene regulation. *Int. J. Oncol.* *54*, 673–688.
- Song, M., Yin, Y., Zhang, J., Zhang, B., Bian, Z., Quan, C., Zhou, L., Hu, Y., Wang, Q., Ni, S., et al. (2014a). MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. *Protein Cell* *5*, 851–861.
- Song, Y., Li, J., Zhu, Y., Dai, Y., Zeng, T., Liu, L., Li, J., Wang, H., Qin, Y., Zeng, M., et al. (2014b). MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. *Oncotarget* *5*, 11669–11680.
- Sun, H., and Jiang, P. (2018). MicroRNA-451a acts as tumor suppressor in cutaneous basal cell carcinoma. *Mol. Genet. Genomic Med.* *6*, 1001–1009.
- Sun, X., and Zhang, L. (2017). MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2. *Biosci. Rep.* *37*.

Sun, C., Li, N., Yang, Z., Zhou, B., He, Y., Weng, D., Fang, Y., Wu, P., Chen, P., Yang, X., et al. (2013a). MiR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. *J. Natl. Cancer Inst.* *105*, 1750–1758.

Sun, C., Sang, M., Li, S., Sun, X., Yang, C., Xi, Y., Wang, L., Zhang, F., Bi, Y., Fu, Y., et al. (2015). Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. *Oncotarget* *6*, 39756–39792.

Sun, Z., Han, Q., Zhou, N., Wang, S., Lu, S., Bai, C., and Zhao, R.C. (2013b). MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. *Mol. Oncol.* *7*, 884–894.

Tang, H., Yao, L., Tao, X., Yu, Y., Chen, M., Zhang, R., and Xu, C. (2013). MiR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN. *Int. J. Mol. Med.* *32*, 381–388.

Tang, H., Li, K., Zheng, J., Dou, X., Zhao, Y., and Wang, L. (2019). microRNA-145 regulates tumor suppressor candidate 3 and mitogen-activated protein kinase pathway to inhibit the progression of colorectal cancer. *J. Cell. Biochem.* *120*, 8376–8384.

Tian, F., Han, Y., Yan, X., Zhong, D., Yang, G., Lei, J., Li, X., and Wang, X. (2016). Upregulation of microRNA-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. *Thorac. Cancer* *7*, 226–231.

Tian, W., Du, Y., Ma, Y., Zhang, B., Gu, L., Zhou, J., and Deng, D. (2019). MiR663a-TTC22V1 axis inhibits colon cancer metastasis. *Oncol. Rep.* *41*, 1718–1728.

Troschel, F.M., Böhly, N., Borrmann, K., Braun, T., Schwickert, A., Kiesel, L., Eich, H.T., Götte, M., and Greve, B. (2018). miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. *Tumor Biol.* *40*, 101042831879188.

Uchida, A., Seki, N., Mizuno, K., Yamada, Y., Misono, S., Sanada, H., Kikkawa, N., Kumamoto, T., Suetsugu, T., and Inoue, H. (2019). Regulation of KIF2A by antitumor miR-451a inhibits cancer cell aggressiveness features in lung squamous cell carcinoma. *Cancers (Basel)*. *11*.

Varshney, A., Panda, J.J., Singh, A.K., Yadav, N., Bihari, C., Biswas, S., Sarin, S.K., and Chauhan, V.S. (2018). Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice. *Hepatology* *67*, 1392–1407.

Wang, Z. (2014). MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/ $\beta$ -catenin signaling pathway. *Oncogene* *33*, 5017–5027.

Wang, B., Yang, J., and Xiao, B. (2016). MicroRNA-20b (miR-20b) promotes the proliferation, migration, invasion, and tumorigenicity in esophageal cancer cells via the regulation of phosphatase and tensin homologue expression. *PLoS One* *11*.

Wang, G., Sun, D., Li, W., and Xin, Y. (2020). AKNA Is a Potential Prognostic Biomarker in Gastric Cancer and Function as a Tumor Suppressor by Modulating EMT-Related Pathways. *Biomed Res. Int.* *2020*.

Wang, H., Wu, Q., Zhang, Y., Zhang, H.N., Wang, Y. Bin, and Wang, W. (2017a). TGF- $\beta$ 1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. *Cell. Mol. Biol. Lett.* *22*.

- Wang, J., Wang, B., Ren, H.Q., and Chen, W. (2019). miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting GOT1. *Biochem. Biophys. Res. Commun.* *509*, 241–248.
- Wang, K., Jin, J., Ma, T., and Zhai, H. (2017b). MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9. *J. Cell. Mol. Med.* *21*, 3730–3740.
- Wang, L.K., Hsiao, T.H., Hong, T.M., Chen, H.Y., Kao, S.H., Wang, W.L., Yu, S.L., Lin, C.W., and Yang, P.C. (2014a). MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. *PLoS One* *9*.
- Wang, Q., Xu, B., Du, J., Xu, X., Shang, C., Wang, X., and Wang, J. (2018a). MicroRNA-139-5p/Flt1/Wnt/ $\beta$ -catenin regulatory crosstalk modulates the progression of glioma. *Int. J. Mol. Med.* *41*, 2139–2149.
- Wang, S.H., Zhou, J. Da, He, Q.Y., Yin, Z.Q., Cao, K., and Luo, C.Q. (2014b). MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. *Int. J. Clin. Exp. Pathol.* *7*, 7131–7141.
- Wang, W., Corrigan-Cummins, M., Hudson, J., Maric, I., Simakova, O., Neelapu, S.S., Kwak, L.W., Janik, J.E., Gause, B., Jaffe, E.S., et al. (2012). MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. *Haematologica* *97*, 586–594.
- Wang, X., Wang, K., Han, L., Zhang, A., Shi, Z., Zhang, K., Zhang, H., Yang, S., Pu, P., Shen, C., et al. (2013). PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/ $\beta$ -catenin pathway in a Dkk1-dependent manner during glioma growth. *Cancer Lett.* *331*, 211–219.
- Wang, Y., Li, J., Xu, C., and Zhang, X. (2018b). MicroRNA-139-5p inhibits cell proliferation and invasion by targeting RHO-associated coiled-coil-containing protein kinase 2 in ovarian cancer. *Oncol. Res.* *26*, 411–420.
- Wang, Z., Ma, X., Cai, Q., Wang, X., Yu, B., Cai, Q., liu, B., Zhu, Z., and Li, C. (2014c). MiR-199a-3p promotes gastric cancer progression by targeting ZHX1. *FEBS Lett.* *588*, 4504–4512.
- Wei, A.W., and Li, L.F. (2017). Long non-coding RNA SOX21-AS1 sponges miR-145 to promote the tumorigenesis of colorectal cancer by targeting MYO6. *Biomed. Pharmacother.* *96*, 953–959.
- Wei, G.Y., Hu, M., Zhao, L., and Guo, W.S. (2019). MiR-451a suppresses cell proliferation, metastasis and EMT via targeting YWHAZ in hepatocellular carcinoma. *Eur. Rev. Med. Pharmacol. Sci.* *23*, 5158–5167.
- Weiss, F.U., Marques, I.J., Woltering, J.M., Vlecken, D.H., Aghdassi, A., Partecke, L.I., Heidecke, C.D., Lerch, M.M., and Bagowski, C.P. (2009). Retinoic Acid Receptor Antagonists Inhibit miR-10a Expression and Block Metastatic Behavior of Pancreatic Cancer. *Gastroenterology* *137*.
- Wong, C.C., Wong, C., Tung, E.K., Au, S.L., Lee, J.M., Poon, R.T., Man, K., and Ng, I.O. (2011). The MicroRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating rho-kinase 2. *Gastroenterology* *140*, 322–331.
- Wong, T.S., Liu, X.B., Ho, A.C.W., Yuen, A.P.W., Ng, R.W.M., and Wei, W.I. (2008). Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. *Int. J. Cancer* *123*, 251–257.

- Wu, J., Zhang, T., Chen, Y., and Ha, S. (2020a). MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression. *Biosci. Rep.* *40*, 20193295.
- Wu, L., Cai, C., Wang, X., Liu, M., Li, X., and Tang, H. (2011). MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. *FEBS Lett.* *585*, 1322–1330.
- Wu, P., Cai, J., Chen, Q., Han, B., Meng, X., Li, Y., Li, Z., Wang, R., Lin, L., Duan, C., et al. (2019a). Lnc-TALC promotes O<sup>6</sup>-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. *Nat. Commun.* *10*.
- Wu, Y., Zhou, Y., Huan, L., Xu, L., Shen, M., Huang, S., and Liang, L. (2019b). LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells. *Cancer Sci.* *110*, 973–984.
- Wu, Y., Li, H., Xie, J., Wang, F., Cao, D., and Lou, Y. (2020b). MiR-139-5p affects cell proliferation, migration and adipogenesis by targeting insulin-like growth factor 1 receptor in hemangioma stem cells. *Int. J. Mol. Med.* *45*, 569–577.
- Xia, C., Liang, S., He, Z., Zhu, X., Chen, R., and Chen, J. (2018). Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. *Eur. J. Pharmacol.* *830*, 59–67.
- Xia, L., Li, F., Qiu, J., Feng, Z., Xu, Z., Chen, Z., and Sun, J. (2020). Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1. *BMC Cancer* *20*.
- Xie, H., Ren, X., Xin, S., Lan, X., Lu, G., Lin, Y., Yang, S.S., Zeng, Z.C., Liao, W.T., Ding, Y.Q., et al. (2016). Emerging roles of circRNA\_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. *Oncotarget* *7*, 26680–26691.
- Xie, H.H., Huan, W.T., Han, J.Q., Ren, W.R., and Yang, L.H. (2019). MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2. *Biol. Res.* *52*, 18.
- Xiong, G., Huang, H., Feng, M., Yang, G., Zheng, S., You, L., Zheng, L., Hu, Y., Zhang, T., and Zhao, Y. (2018). MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. *J. Exp. Clin. Cancer Res.* *37*, 76.
- Xu, K., Han, B., Bai, Y., Ma, X.Y., Ji, Z.N., Xiong, Y., Miao, S.K., Zhang, Y.Y., and Zhou, L.M. (2019a). MiR-451a suppressing BAP31 can inhibit proliferation and increase apoptosis through inducing ER stress in colorectal cancer. *Cell Death Dis.* *10*.
- Xu, P., Li, Y., Yang, S., Yang, H., Tang, J., and Li, M. (2015a). Micro-ribonucleic acid 143 (MiR-143) inhibits oral squamous cell carcinoma (OSCC) cell migration and invasion by downregulation of phospho-c-Met through targeting CD44 v3. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* *120*, 43–51.
- Xu, Q., Liu, L.Z., Qian, X., Chen, Q., Jiang, Y., Li, D., Lai, L., and Jiang, B.H. (2012). MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. *Nucleic Acids Res.* *40*, 761–774.

- Xu, S., Wei, J., Wang, F., Kong, L.Y., Ling, X.Y., Nduom, E., Gabrusiewicz, K., Doucette, T., Yang, Y., Yaghi, N.K., et al. (2014). Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. *J. Natl. Cancer Inst.* *106*.
- Xu, W.-X., Liu, Z., Deng, F., Wang, D.-D., Li, X.-W., Tian, T., Zhang, J., and Tang, J.-H. (2019b). MiR-145: a potential biomarker of cancer migration and invasion. *Am. J. Transl. Res.* *11*, 6739–6753.
- Xu, W., Hang, M., Yuan, C.Y., Wu, F.L., Chen, S.B., and Xue, K. (2015b). MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. *Int. J. Clin. Exp. Pathol.* *8*, 3864–3870.
- Xu, Y., Zhang, X., Hu, X., Zhou, W., Zhang, P., Zhang, J., Yang, S., and Liu, Y. (2018). The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. *Mol. Med.* *24*.
- Xu, Z., Ji, J., Xu, J., Li, D., Shi, G., Liu, F., Ding, L., Ren, J., Dou, H., Wang, T., et al. (2017). MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma. *FEBS J.* *284*, 2410–2424.
- Xue, T.M., Tao, L. De, Zhang, M., Zhang, J., Liu, X., Chen, G.F., Zhu, Y.J., and Zhang, P.J. (2015). Clinicopathological significance of MicroRNA-20b expression in hepatocellular carcinoma and regulation of HIF-1  $\alpha$  and VEGF effect on cell biological behaviour. *Dis. Markers* *2015*.
- Yamada, Y., Arai, T., Sugawara, S., Okato, A., Kato, M., Kojima, S., Yamazaki, K., Naya, Y., Ichikawa, T., and Seki, N. (2018a). Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma. *Cancer Sci.* *109*, 1239–1253.
- Yamada, Y., Koshizuka, K., Hanazawa, T., Kikkawa, N., Okato, A., Idichi, T., Arai, T., Sugawara, S., Katada, K., Okamoto, Y., et al. (2018b). Passenger strand of miR-145-3p acts as a tumor-suppressor by targeting MYO1B in head and neck squamous cell carcinoma. *Int. J. Oncol.* *52*, 166–178.
- Yamasaki, T., Yoshino, H., Enokida, H., Hidaka, H., Chiyomaru, T., Nohata, N., Kinoshita, T., Fuse, M., Seki, N., and Nakagawa, M. (2012). Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. *Int. J. Oncol.* *40*, 1821–1830.
- Yan, Y., Luo, Y.-C., Wan, H.-Y., Wang, J., Zhang, P.-P., Liu, M., Li, X., Li, S., and Tang, H. (2013). MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-Mediated epithelial-mesenchymal transition and adhesion in hepatoma cells\*. *Hepatology* *57*, 667–677.
- Yang, X., Chen, Y., and Chen, L. (2017). The versatile role of microRNA-30a in human cancer. *Cell. Physiol. Biochem.* *41*, 1616–1632.
- Ye, D., Zhou, C., Deng, H., Lin, L., and Zhou, S. (2019). MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/ Akt signaling pathway. *Cancer Manag. Res.* *11*, 3801–3812.
- Yonemori, M., Seki, N., Yoshino, H., Matsushita, R., Miyamoto, K., Nakagawa, M., and Enokida, H. (2016). Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. *Cancer Sci.* *107*, 1233–1242.



- Yoshino, H., Chiyomaru, T., Enokida, H., Kawakami, K., Tatarano, S., Nishiyama, K., Nohata, N., Seki, N., and Nakagawa, M. (2011). The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. *Br. J. Cancer* *104*, 808–818.
- Yu, T., Liu, L., Li, J., Yan, M., Lin, H., Liu, Y., Chu, D., Tu, H., Gu, A., and Yao, M. (2015). MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. *Oncotarget* *6*, 30239–30250.
- Yuan, S., Xiang, Y., Wang, G., Zhou, M., Meng, G., Liu, Q., Hu, Z., Li, C., Xie, W., Wu, N., et al. (2019). Hypoxia-sensitive LINC01436 is regulated by E2F6 and acts as an oncogene by targeting miR-30a-3p in non-small cell lung cancer. *Mol. Oncol.* *13*, 840–856.
- Zang, C., Zhao, F., Hua, L., and Pu, Y. (2018). The miR-199a-3p regulates the radioresistance of esophageal cancer cells via targeting the AK4 gene. *Cancer Cell Int.* *18*, 186.
- Zeng, T., and Li, G. (2014). MicroRNA-10a enhances the metastatic potential of cervical cancer cells by targeting phosphatase and tensin homologue. *Mol. Med. Rep.* *10*, 1377–1382.
- Zhang, C., Chen, B., Jiao, A., Li, F., Sun, N., Zhang, G., and Zhang, J. (2018a). miR-663a inhibits tumor growth and invasion by regulating TGF- $\beta$ 1 in hepatocellular carcinoma. *BMC Cancer* *18*, 1179.
- Zhang, E., Liu, Q., Wang, Y., Wang, H., He, L., Jin, X., and Li, N. (2017). MicroRNA miR-147b promotes tumor growth via targeting UBE2N in hepatocellular carcinoma. *Oncotarget* *8*, 114072–114080.
- Zhang, H., Li, Y., Tan, Y., Liu, Q., Jiang, S., Liu, D., Chen, Q., and Zhang, S. (2019). MiR-9-5p Inhibits Glioblastoma Cells Proliferation Through Directly Targeting FOXP2 (Forkhead Box P2). *Front. Oncol.* *9*, 1176.
- Zhang, J., Sun, Q., Zhang, Z., Ge, S., Han, Z.G., and Chen, W.T. (2013). Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. *Oncogene* *32*, 61–69.
- Zhang, K., Wu, L., Zhang, P., Luo, M., Du, J., Gao, T., O’Connell, D., Wang, G., Wang, H., and Yang, Y. (2018b). miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma. *Mol. Carcinog.* *57*, 1566–1576.
- Zhang, L., Dong, Y., Zhu, N., Tsoi, H., Zhao, Z., Wu, C.W., Wang, K., Zheng, S., Ng, S.S.M., Chan, F.K.L., et al. (2014). MicroRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. *Mol. Cancer* *13*, 124.
- Zhang, W., Liu, K., Liu, S., Ji, B., Wang, Y., and Liu, Y. (2015). MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. *Tumor Biol.* *36*, 9779–9788.
- Zhang, X., Qian, Y., Li, F., Bei, S., Li, M., and Feng, L. (2018c). microRNA-9 selectively targets LMX1A to promote gastric cancer cell progression. *Biochem. Biophys. Res. Commun.* *505*, 405–412.
- Zhang, Y., Zhang, H., and Liu, Z. (2016a). MicroRNA-147 suppresses proliferation, invasion and migration through the AKT/mTOR signaling pathway in breast cancer. *Oncol. Lett.* *11*, 405–410.

Zhang, Y., Xu, X., Zhang, M., Wang, X., Bai, X., Li, H., Kan, L., Zhou, Y., Niu, H., and He, P. (2016b). MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD. *BMC Cancer* *16*, 315.

Zhang, Z., Li, W., Jiang, D., Liu, C., and Lai, Z. (2020). MicroRNA-139-5p inhibits cell viability, migration and invasion and suppresses tumor growth by targeting HDGF in non-small cell lung cancer. *Oncol. Lett.* *19*, 1806–1814.

Zhao, H., Li, M., Li, L., Yang, X., Lan, G., and Zhang, Y. (2013). MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. *PLoS One* *8*.

Zhou, B., Xu, H., Xia, M., Sun, C., Li, N., Guo, E., Guo, L., Shan, W., Lu, H., Wu, Y., et al. (2017). Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer. *Front. Med.* *11*, 214–222.

Zhou, H., Zhang, L., and Tu, H. (2019). Downregulation of thymopoietin by miR-139-5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma. *Oncol. Lett.* *18*, 3443–3452.

Zhou, W., Shi, G., Zhang, Q., Wu, Q., Li, B., and Zhang, Z. (2014). MicroRNA-20b promotes cell growth of breast cancer cells partly via targeting phosphatase and tensin homologue (PTEN). *Cell Biosci.* *4*, 62.

Zhu, J., Chen, L., Zou, L., Yang, P., Wu, R., Mao, Y., Zhou, H., Li, R., Wang, K., Wang, W., et al. (2014). MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. *Hum. Immunol.* *75*, 348–353.

Zhu, S.W., Li, J.P., Ma, X.L., Ma, J.X., Yang, Y., Chen, Y., and Liu, W. (2015). miR-9 modulates osteosarcoma cell growth by targeting the GCIIP tumor suppressor. *Asian Pacific J. Cancer Prev.* *16*, 4509–4513.

Zhu, Y., Tang, H., Zhang, L., Gong, L., Wu, G., Ni, J., and Tang, X. (2019). Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN. *Cancer Manag. Res.* *11*, 955–968.